To the Editor, {#s1a}
==============

The publication "Wilm's tumor-1 (WT1) rs16754 Polymorphism and Clinical Outcome in Acute Myeloid Leukemia" was very interesting \[[@ref1]\]. Ramzi et al. \[[@ref1]\] noted that "*WT1* rs16754 polymorphism may be a reliable independent prognostic factor". In fact, the *WT1* rs16754 polymorphism is proposed as an important prognostic marker for leukemia \[[@ref2]\]. The application in the present study might be expected. However, there can also be interference effects of other polymorphisms (such as MDM2 \[[@ref3]\] and long non-coding RNA GAS5 polymorphism \[[@ref4]\]) that were not investigated that might modify the value of *WT1* rs16754 polymorphism testing. Single polymorphism study might limit its application in clinical usage for prognosis prediction for leukemia patients.

**Conflict of Interest:** The authors of this paper have no conflicts of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.
